U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07135323) titled 'AvertD Post-Approval Study' on July 17.
Brief Summary: A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
Study Start Date: Nov. 15, 2024
Study Type: OBSERVATIONAL
Condition:
Opioid Use Disorder
Intervention:
GENETIC: Opioid Used Disorder Risk Assessment
Determine the likelihood of Opioid Used Disorder prior to prescribing opioids
Recruitment Status: RECRUITING
Sponsor: Prescient Medicine Holdings, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....